ReviewCurrent opinion in biotechnology2021
Enhancing phage therapy through synthetic biology and genome engineering.
Review in Current opinion in biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 116 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
116 citing papers in PubMed, 2 syntheses or guidelines pooled it, 181 citations in OpenAlex.
- CRISPR-Cas systems as next-generation antimicrobials: a systemic review of mechanisms, delivery strategies, and translational challenges.Frontiers in microbiology · 2026Pooled it
- Evolutionary dynamics and research hotspots of phage applications againstFrontiers in microbiology · 2026Pooled it
- Phage Genomics and Bioinformatics in Therapeutic Development: Evidence Limits, Validation Gates, and Translational Decision-Making.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Prophage-Derived Molecules as Anti-Antibiotics (Basel, Switzerland) · 2026Review
- Phage Therapy Enhanced by Using Engineered Bacteriophages: A Powerful Antibacterial Tool to Address the Dilemma Posed by Multidrug-Resistant Bacterial Infections.International journal of molecular sciences · 2026Review
- Characterization of a novel phage-plasmid vB_EcoM_ED targeting multidrug-resistant Escherichia coli isolates.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Artificial Intelligence in Bacteriophage Science: A Comprehensive Narrative Review of Applications, Challenges, and Translational Opportunities.Antibiotics (Basel, Switzerland) · 2026Review
- Transplantation of encapsulated fecal microbiota: research progress and future trends.World journal of pediatrics : WJP · 2026Review
- Potential of phage therapy for the treatment of diabetic foot infections.Folia microbiologica · 2026Review
- Isolation, genomic characterization, and biofilm eradication activity of vB_PaP_DMTU_1, a novel lytic bacteriophage against Pseudomonas aeruginosa.Folia microbiologica · 2026Article
- Insight into Bacteriophage Therapy for Bacterial Infections and Cancer.Molecular biotechnology · 2026Review
- Phage-Microbiota Interactions in the Gut: Implications for Health and Therapeutic Strategies.Probiotics and antimicrobial proteins · 2026Review
- Bacteriophages as Therapeutic Agents for Pulmonary Infections: From Biological Principles to Clinical Applications.Pharmaceutics · 2026Review
- From structure to design: experimental and AI-driven approaches in receptor-binding protein engineering for reprogramming phage host range.Archives of microbiology · 2026Review
- Phage-Based Approaches to ChronicAntibiotics (Basel, Switzerland) · 2026Review
- A fully synthetic Golden Gate assembly system for engineering aProceedings of the National Academy of Sciences of the United States of America · 2026Article
- Vancomycin resistance in gram-positive infections: evolutionary strategies of survival.Archives of microbiology · 2026Review
- Recoded Bacteriophage Genome for Bio-Orthogonal-Enabled Concentration and Detection ofACS synthetic biology · 2026Article
- Antimicrobial Resistance: How Can We Overcome the Problem?Antibiotics (Basel, Switzerland) · 2026Review
- Limitations and safety aspects related to the use of bacteriophages in food production.FEMS microbiology reviews · 2026Article
56 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
The antimicrobial and therapeutic efficacy of bacteriophages is currently limited, mostly due to rapid emergence of phage-resistance and the inability of most phage isolates to bind and infect a broad range of clinical strains. Here, we discuss how phage therapy can be improved through recent advances in genetic engineering. First, we outline how receptor-binding proteins and their relevant structural domains are engineered to redirect phage specificity and to avoid resistance. Next, we summarize how phages are reprogrammed as prokaryotic gene therapy vectors that deliver antimicrobial 'payload' proteins, such as sequence-specific nucleases, to target defined cells within complex microbiomes. Finally, we delineate big data- and novel artificial intelligence-driven approaches that may guide the design of improved synthetic phage in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.